Skip to content

TOAST

Temperature Optimization in Afebrile Septic patienTs (TOAST) study - TOAST

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58549
Enrollment
50
Registered
2025-07-21
Start date
2026-07-17
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis blood poisoning

Interventions

Patients in the intervention group will receive 48 hours of external warming with a temperature management system (Artic Sun) to a goal core temperature 1.5°C greater than the lowest recorded temperat

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: >18 years of age•           Within 48 hours of sepsis (defined as the date/time of the first order for antibiotics)•           Requirement for mechanical ventilation•           Maximum temperature < 38.3°C within the 24 hours prior to enrollment. * Meeting the SEPSIS-3 definition for sepsis: suspected or confirmed infection and an acute increase in the Sequential Organ Failure Assessment (SOFA) score by =2 points, indicating organ dysfunction.

Exclusion criteria

Exclusion criteria:  Patients with immunologic diseases:HIVneutropeniahistory of chronic infection with hepatitis B or C virusPatients using immune suppressing medications:treatment with corticosteroids at a dose of > 300 mg/day hydrocortisone or equivalent at the time of enrollment; TacrolimusMMFCiclofosfamide Patients with a contraindication for therapeutic hyperthermia: cardiac arrestacute ischemic strokeacute coronary syndrometraumatic brain injuryspinal cord injury sickle cell diseasemultiple sclerosisPregnancyMoribund patients (expected death within 48 hours)Contraindications to forced air warming devices per manufacture instructions (i.e. ischemic limbs)

Design outcomes

Primary

MeasureTime frame
Exploratory proteomics analysis 

Secondary

MeasureTime frame
Clinical endpoints, macro and microhemodynamic measurements

Countries

Netherlands

Contacts

Public ContactN. Juffermans

Erasmus Universiteit Rotterdam

n.juffermans@erasmusmc.nl0641813457

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 10, 2026